Abstract
The elevated level of dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) is associated with the pathology of neurodegenerative diseases and has been implicated in some neurobiological alterations of Down syndrome, such as mental retardation. In the present article, a pharmacophore based 3D-QSAR model was developed for a series of leucettines possessing Dyrk1A inhibitory activity. The crucial molecular features observed in the developed pharmacophore model that account for binding affinity of ligands with the enzyme, include three H-bond acceptors (A), one positive ionic site (P) and one hydrophobic aromatic ring (R). Excellent statistical results of QSAR model such as good correlation coefficient (r > 0.9), higher F value (F > 20), excellent predictive power (Q2 > 0.6) and higher enrichment of known actives during virtual screening application strongly suggest that the developed model will be highly useful in designing new inhibitors and for predicting activity of new inhibitors.
Keywords: Anti-Alzheimers, Dyrk1A, Leucettines, Pharmacophore model, 3D-QSAR, Partial least square analysis.
Letters in Drug Design & Discovery
Title:Pharmacophore Based 3D-QSAR Modeling and Molecular Docking of Leucettines as Potent Dyrk1A Inhibitors
Volume: 10 Issue: 8
Author(s): Anu Bahl, Prashant Joshi, Sandip B. Bharate and Harish Chopra
Affiliation:
Keywords: Anti-Alzheimers, Dyrk1A, Leucettines, Pharmacophore model, 3D-QSAR, Partial least square analysis.
Abstract: The elevated level of dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) is associated with the pathology of neurodegenerative diseases and has been implicated in some neurobiological alterations of Down syndrome, such as mental retardation. In the present article, a pharmacophore based 3D-QSAR model was developed for a series of leucettines possessing Dyrk1A inhibitory activity. The crucial molecular features observed in the developed pharmacophore model that account for binding affinity of ligands with the enzyme, include three H-bond acceptors (A), one positive ionic site (P) and one hydrophobic aromatic ring (R). Excellent statistical results of QSAR model such as good correlation coefficient (r > 0.9), higher F value (F > 20), excellent predictive power (Q2 > 0.6) and higher enrichment of known actives during virtual screening application strongly suggest that the developed model will be highly useful in designing new inhibitors and for predicting activity of new inhibitors.
Export Options
About this article
Cite this article as:
Bahl Anu, Joshi Prashant, Bharate B. Sandip and Chopra Harish, Pharmacophore Based 3D-QSAR Modeling and Molecular Docking of Leucettines as Potent Dyrk1A Inhibitors, Letters in Drug Design & Discovery 2013; 10 (8) . https://dx.doi.org/10.2174/15701808113100890024
DOI https://dx.doi.org/10.2174/15701808113100890024 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative and Non-Oxidative Metabolomics of Ethanol
Current Drug Metabolism ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Impact of Crystallographic Data for the Development of Machine Learning Models to Predict Protein-Ligand Binding Affinity
Current Medicinal Chemistry Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Single-chain Antibody Against Reg4 Suppresses Gastric Cancer Cell Growth and Enhances 5-FU-induced Cell Death in vitro
Anti-Cancer Agents in Medicinal Chemistry Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design Mitochondria as Targets for Neuronal Protection Against Excitotoxicity: A Role for Phenolic Compounds?
Central Nervous System Agents in Medicinal Chemistry What Animal Models Have Taught us About Adenosine Receptor Function
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Exercise-Induced Cardiac Troponin Release: Real-Life Clinical Confusion
Current Medicinal Chemistry Recent Advance of Computational Approaches in Genomics and Proteomics
Current Bioinformatics Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Current Medicinal Chemistry Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Electrode in the Brain: Some Engineering Aspects of Deep Brain Stimulation
Neuroscience and Biomedical Engineering (Discontinued) Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design A Novel Nanoformulation of Ellagic Acid is Promising in Restoring Oxidative Homeostasis in Rat Brains with Alzheimer’s Disease
Current Drug Metabolism An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Life Under Stress: The Probiotic Stress Response and How it may be Manipulated
Current Pharmaceutical Design